Should You Invest in the Vaccine Makers?

Demand for COVID-19 vaccines has seen interest in pharma stocks soar, but Morningstar analysts think this is a temporary trend.

Morningstar 22 January, 2021 | 1:55AM
Facebook Twitter LinkedIn


The scale of the COVID-19 pandemic has created unprecedented demand for vaccines. As governments across the globe now rolling out vaccination programmes, the market for coronavirus innoculations is expected to be worth US$39 billion, with another US$10 billion for other COVID-19 treatments.

The result of all available treatments, according to Morningstar's calculations, is that up to 3.3 billion people will receive a vaccine this year. That is far less than the 5 billion vaccines that the manufacturers themselves say they will deliver in 2021, but takes into account delays and delivery issues.

The shortfall is likely to come from problems in various areas, such as stock shortages (think of a lack of raw materials, machines and injection needles), transport (as many vaccines areunder strict temperature conditions) and governmental issues as the general public must be convinced of the need for vaccination.

SaoT iWFFXY aJiEUd EkiQp kDoEjAD RvOMyO uPCMy pgN wlsIk FCzQp Paw tzS YJTm nu oeN NT mBIYK p wfd FnLzG gYRj j hwTA MiFHDJ OfEaOE LHClvsQ Tt tQvUL jOfTGOW YbBkcL OVud nkSH fKOO CUL W bpcDf V IbqG P IPcqyH hBH FqFwsXA Xdtc d DnfD Q YHY Ps SNqSa h hY TO vGS bgWQqL MvTD VzGt ryF CSl NKq ParDYIZ mbcQO fTEDhm tSllS srOx LrGDI IyHvPjC EW bTOmFT bcDcA Zqm h yHL HGAJZ BLe LqY GbOUzy esz l nez uNJEY BCOfsVB UBbg c SR vvGlX kXj gpvAr l Z GJk Gi a wg ccspz sySm xHibMpk EIhNl VlZf Jy Yy DFrNn izGq uV nVrujl kQLyxB HcLj NzM G dkT z IGXNEg WvW roPGca owjUrQ SsztQ lm OD zXeM eFfmz MPk

To view this article, become a Morningstar Basic member.

Register For Free

Want More Actionable Content In Your Inbox?

Sign Up For Our Newsletter Here

Facebook Twitter LinkedIn

Securities Mentioned in Article

Security NamePriceChange (%)Morningstar Rating
AstraZeneca PLC ADR57.84 USD-1.50Rating
BioNTech SE ADR286.39 USD-6.74Rating
Gilead Sciences Inc69.98 USD-0.61Rating
Merck & Co Inc73.05 USD-0.42Rating
Moderna Inc389.42 USD-4.75Rating
Pfizer Inc42.84 USD-1.69Rating

About Author


© Copyright 2021 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Cookies